You have 9 free searches left this month | for more free features.

evobrutinib

Showing 1 - 11 of 11

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Healthy Trial in Neu-Ulm (Evobrutinib, Carbamazepine)

Recruiting
  • Healthy
  • Neu-Ulm, Bavaria, Germany
    Nuvisan GmbH
Feb 9, 2022

Healthy Trial in Neu-Ulm (Evobrutinib, Digoxin, Metformin)

Completed
  • Healthy
  • Evobrutinib
  • +4 more
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jan 10, 2022

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Healthy Trial in Groningen (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Groningen, Netherlands
    PRA Health Sciences
Jul 3, 2020

Healthy Trial in Neu-Ulm (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jul 3, 2020

Healthy Trial in Neu-Ulm (Evobrutinib)

Completed
  • Healthy
  • Evobrutinib
  • Neu-Ulm, Germany
    Nuvisan GmbH
Jul 8, 2020

Relapsing-remitting Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo, Tecfidera)

Active, not recruiting
  • Relapsing-remitting Multiple Sclerosis
  • Evobrutinib
  • +2 more
  • Blagoevgrad, Bulgaria
  • +55 more
May 4, 2021

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Cullman, Alabama
  • +275 more
Nov 7, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Evobrutinib, Placebo (match to Teriflunomide), Teriflunomide)

Active, not recruiting
  • Relapsing Multiple Sclerosis
  • Evobrutinib
  • +3 more
  • Mobile, Alabama
  • +278 more
Nov 7, 2022

Renal Impairment Trial in Darmstadt (Evobrutinib)

Completed
  • Renal Impairment
  • Evobrutinib
  • Darmstadt, Germany
    Please Contact the Merck KGaA Communication Center
May 15, 2019